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ABSTRACT
Objective: Stroke is one of the leading causes of death and disabilities worldwide. Cost-effectiveness analysis helps identify neglected opportunities 
by highlighting interventions that are relatively inexpensive, yet have the potential to reduce the disease burden substantially. In India, there are 
wide social and economic disparities. Socioeconomic environment influences occupation, lifestyle, and nutrition of social classes which in turn would 
influence the prevalence and profile of stroke. By reduction of delays in access to hospital and improving provision of affordable treatments can 
reduce morbidity and mortality in patients with stroke in India. This study is designed to measure and compare the costs (resources consumed) and 
consequences (clinical, economic, and humanistic) of pharmaceutical products and services and their impact on individuals, healthcare systems and 
society.
Methods: The purpose of this study is to analyze and conduct a cost-effectiveness analysis for the treatment of stroke in Guntur City Hospitals. 
The patients were treated either with aspirin or clopidogrel. The health outcomes were measured using Modified Rankin Scale, A prominent risk 
assessment scale for stroke. The pharmacoeconomic data were computed from the patient data collection forms.
Result: The incremental cost-effectiveness ratio of aspirin and clopidogrel were calculated to be Rs. 8046.2/year.
Conclusion: The study concludes that aspirin has the increased socioeconomic impact when compared to Clopidogrel and we can see that the earlier 
therapy has supported discharge, home-based rehabilitation along with reduced hospital stay and hence preferable.
Keywords: Stroke, Pharmacoeconomics, Cost-effectiveness analysis, Aspirin, Clopidogrel, Incremental cost-effectiveness ratio.
INTRODUCTION
Stroke is one of the leading causes of death and disabilities worldwide. In 
developing countries like Australia, United Kingdom, Canada, New Zealand, 
Korea, and Taiwan, there is a lot of economic impact on the stroke [1-6]. 
Recently, even in India, a lot of epidemiological data has been published 
on stroke [7-9]. Annually, about 16 million first-ever strokes occur in the 
world, causing a total of 5.7 million deaths [10]. As a consequence, stroke 
ranks as the second cause of death in the world population after ischemic 
heart disease (the third only if neoplastic diseases are considered as a 
group) [11]. About 85% of all stroke deaths are registered in low- and 
middle-income countries, which also account for 87% of the total losses 
due to stroke in terms of disability-adjusted life years calculated worldwide, 
in 72 million/year [12]. However, many people do not even know the 
economic burden the stroke condition gives to a patient. The health-care 
system in India is also different from other countries [13]. Even though 
Government hospitals are available, the private sector plays a major role in 
Health care. Health insurance covers only 10% of people and old people are 
not covered by health insurance policies [14]. The cost of treating a stroke 
patient can thus differ from other regions of the world.
Pricing of medicines is a very sensitive issue for a developing country 
like India. The pricing causes direct effects on the patients as well as 
it determines the treatment compliance and also the availability of 
various brands in our country [15]. Pharmacoeconomics is a collection 
of descriptive and analytic techniques for evaluating Pharmaceutical 
interventions in health care system [16]. Pharmacoeconomics is a 
branch of health economics, which particularly focuses on the “costs 
and benefits of drug therapy” [17].
Pharmacoeconomic research identifies measures and compares:
•	 Costs	(resources	consumed)	and
•	 Consequences	(clinical,	economic,	and	humanistic)	of	pharmaceutical	
products and services and their impact on individuals, health-care 
systems, and society.
Pharmacoeconomics would also result injudicious spending of 
resources available for healthcare [18]. Cost-effectiveness analysis is a 
method for assessing the gains in health relative to the costs of different 
health interventions. It is not the only criterion for deciding how to 
allocate resources, but it is an important one because it directly relates 
the financial and scientific implications of different interventions. 
Cost-effectiveness analysis helps identify neglected opportunities by 
highlighting interventions that are relatively inexpensive, yet have 
the potential to reduce the disease burden substantially. One of the 
advantages of using cost-effectiveness ratios is that they avoid some 
ethical dilemmas and analytical difficulties that arise when attempting 
cost-benefit analyses [19].
Socioeconomic environment influences occupation, lifestyle, and 
nutrition of social classes which in turn would influence the prevalence 
and profile of stroke. There are a number of studies on the cost treatment 
in patients with stroke from the developed countries very few from the 
developing countries. All expenditure incurred for the direct cost is met 
out-of-pocket by the patients. The treatment of stroke is expensive for 
a very large proportion of patients in developing countries like India.
Although the amount spent by the upper and the lower income patients 
are similar, the percentage of the income spent is higher among the low-
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income patients, due to their lower earning. By reduction of delays in 
access to hospital and improving provision of affordable treatments can 
reduce morbidity and mortality in patients with stroke in India. The era, 
in which high-tech care is generally favored, there is little likelihood that 
a less complex and cost-effective therapy will emerge as the preferred 
choice unless there are data to suggest the same. However, comparative 
cost-effectiveness analysis can lead to such insights. Hence, there is a 
need to carry out comparative cost-effective studies among patients 
receiving these therapies [20].
The aims and objectives of the study include:
•	 To	evaluate	the	cost	of	management	of	stroke,	its	predictors,	and	the	
impact on social determinants of the family
•	 To	analyze	and	conduct	a	cost-effectiveness	analysis	for	the	treatment	
of stroke in Guntur City Hospitals
•	 To	evaluate	the	burden	of	cost	in	patients	with	stroke
•	 To	audit	all	the	pharmacotherapy,	quality	of	life	and	cost-effectiveness	
by comparing different drug combinations.
METHODS
The study was a single-center, non-interventional observational 
study conducted over a period of 6 months, i.e. from August 2016 to 
January 2017 in the Department of Neurology, Guntur City Hospital, 
Kothapet, Guntur, and Andhra Pradesh. The data required for the 
study was collected from the patients at Guntur City Hospital, 
Guntur. A total of 100 patients from the Neurology Department were 
taken in the study. An equal number of patients, i.e., 50 each (n=100) 
have been prescribed with aspirin and clopidogrel, respectively. The 
health outcomes were measured using Modified Rankin Scale, A 
prominent risk assessment scale for stroke. The pharmacoeconomic 
data were computed from the patient data collection forms. The 
data were statistically analyzed using SPSS (Statistical Package 
for Social Sciences) with version 24.0 (SPSS Inc., Bengaluru). All 
the continuous variables of normal distribution were presented in 
the form of mean with standard deviation. Statistically, the cost-
effectiveness was determined using the formula of incremental 
cost-effectiveness ratio (ICER) which is recommended by the World 
Health Organization.










Where C1 and E1 are the cost and effect in the intervention group and 
where C2 and E2 are the cost and effect in the control care group.
Inclusion criteria
•	 All	 adult	 inpatients	 of	 age	 >55	 years	 admitted	 to	 neurology	
department
•	 Patients	having	past	and	present	medical	condition	of	ischemic stroke








Health economics enacted the foundation for the branch of 
pharmacoeconomics for collating different health-care interventions, 
especially pharmaceuticals and generating meaningful cost-effective 
solutions for disease management. Policymakers increasingly use cost-
effectiveness analyses to inform decision-making on competing health-
care interventions.
stroke is an important setting, which was a panic for economic 
evaluations because of the wide range of issues involved for the 
individual and society. It is one of the most expensive diseases as far 
as treatment is perturbed, as it generates higher health-care expenses 
than those produced by other disease. The present study enumerates 
to the current movement toward the extensive considerations in cost-
effectiveness analyses. The choice of aspirin over clopidogrel-yielded 
increased health benefits at a minimized cost. The efficacy significantly 
affects the total costs of the disease. We studied the cost (direct medical, 
nonmedical, and indirect) and socioeconomic impact of stroke in 
Guntur, India.
Domains related to physical, mental, emotional, and social functioning 
are included under a multidimensional concept called health-related 
quality of life. It goes beyond direct measures of population health, 
life expectancy, and causes of death, and focuses on the impact health 
status has on quality of life. Valuing health-related quality of life is not 
straightforward, and the use of QALYs requires caution. In the present 
article, we decided to base all QALY values on Modified Rankin Scale. 
Modified Rankin Scale is the most used tool for which we could find 
published values on all events and health states for input into our 
model.
In our study, the age group analysis shows that out of 100 patients, the 
age between 55 and 65 years of age having more number of patients, 
i.e., 74 (74%) stroke patients and 20 (20%) patients were from the age 
group of 66 to 75 years, and finally, 6 (6%) patients were from the age 
group of 76 to 85 years of age. Age group of 55-65-year-old patients was 
mostly affected by stroke (Fig. 1).
Gender-wise distribution shows that out of 100 stroke patients’ males 
were found to be 67 (67%) and females were 33 (33%) (Fig. 2). This 
shows that the males are highly affected by stroke.
Fig. 1: Age-wise distribution of stroke patients (n=100)
Fig. 2: Gender-wise distribution of stroke patients (n=100)
129
Asian J Pharm Clin Res, Vol 10, Issue 7, 2017, 127-130
 Gopi et al. 
When evaluated for the risk factors of stroke majorly for the smoking 
status the analysis showed that out of 100 patients, 62 (62%) were 
smokers and 38 (38%) were non-smokers (Fig. 3). This reveals that 
Smokers are at a higher risk for the occurrence of stroke.
When evaluated for the alcohol consumption status, the analysis 
showed that out of 100 patients, 89 (89%) were alcoholics, whereas 
11 (11%) were non-alcoholics (Fig. 4). This proves the fact that alcohol 
consumption causes higher blood pressure, thereby increasing the risk 
of stroke.
Comorbidities such as hypertension and diabetes mellitus have been 
shown to increase the risk of stroke. In our study, out of 100 patients, 
39 (39%) patients have hypertension, 5 (5%) patients have diabetes 
mellitus, 32 (32%) patients have both hypertension and diabetes 
mellitus, and 24 (24%) patients have no recorded comorbidities 
(Fig. 5). Most of the patients either have hypertension or a treacherous 
combination of hypertension and diabetes mellitus.
The evaluation of quality of life of all the stroke patients receiving 
either the aspirin or the clopidogrel therapy shows that the sum of 
Modified Rankin Scale scores in aspirin is 95 and the sum of Modified 
Rankin Scale scores in clopidogrel is 115 (Fig. 6). The low Modified 
Rankin Scale score in aspirin denotes the increased quality of life 
in the patients receiving Aspirin. The high-Modified Rankin Scale 
in clopidogrel indicates the decreased quality of Life in the patients 
receiving clopidogrel. Compared to clopidogrel, aspirin shows good 
health-related outcomes.
Based on Table 1, the students paired t-test was used to compare the 
cost difference between aspirin and clopidogrel. From the students 
paired t-test, we concluded that aspirin is more cost-effective than 
clopidogrel.
ICER=Rs. 8046.2
The ICER can be calculated by dividing the difference in costs of 
control group and intervention groups with the difference in the 
effects caused by the control group and the interventional group. The 
total costs of the control group, i.e., patients’ prescribed with aspirin 
are evaluated to be Rs. 388219. The total costs of the interventional 
group i.e., patients prescribed with Clopidogrel are evaluated to be Rs. 
549143. The sum of Modified Rankin Scale scores of the control group 
is found to be 95 whereas the sum of Modified Rankin Scale scores of 
the interventional group is found to be 115. The ICER was calculated to 
be Rs. 8046.2 (Table 2). Low ICER than the threshold determines the 
cost-effectiveness of the drug therapy.
This analysis shows that Aspirin is more cost-effective than Clopidogrel 
in the treatment of stroke also offering a favorable adverse effect profile 
and quality of life in comparison to the latter. Stroke, given its chronicity 
and associated morbidity and mortality, constitutes a significant disease 
burden to the society, both in terms of the health-related repercussions 
as well as financial costs incurred due to morbidity and cumulative cost 
of drug therapy. Hence, it is important to administer drugs that are cost-
effective and have minimal side effects. This is particularly important 
in a developing country like India, where the accretive cost of the long-
term therapy is often a significant deterrent to patient compliance. 
The results of this study contribute toward decision-making involved 
in formulary management and by clinicians treating the patients with 
stroke.
CONCLUSION
The study concludes that the pharmacoeconomic evaluation of stoke 
is essential to obtain optimal therapy at lowest price and which 
medication helps the poor and middle-class patients to give appropriate 
health-care service. The cost driving factors in case of aspirin were 
found to be manageable income, better outcomes, and reduced length 
Fig. 3: Details on smoking status (n=100)
Fig. 4: Details on alcohol consumption status (n=100)
Fig. 5: Details on comorbidities/associated conditions that led to 
stroke
Fig. 6: Quality of life evaluation of stroke patients on aspirin/
clopidogrel therapy
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of hospital stay. In contrast, the clopidogrel cost-driving factors were 
higher income, poor outcomes, and increased length of hospital stay. 
Aspirin has the increased socioeconomic impact when compared to 
clopidogrel, and we can see that the earlier therapy has supported 
discharge, home-based rehabilitation along with reduced hospital stay.
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